<DOC>
	<DOC>NCT02755987</DOC>
	<brief_summary>This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1005-CLN-04 with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.</brief_summary>
	<brief_title>Expanded Access to ANG1005 for Individual Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1. Neurologically stable 2. Karnofsky performance status (KPS) ≥ 80 3. Adequate laboratory results 1. Radiotherapy within 3 months. 2. Evidence of significant intracranial hemorrhage 3. NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 Grade ≥ 2 neuropathy 4. Inadequate bone marrow reserve 5. Any evidence of severe or uncontrolled disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>